Related Experiment Video
Updated: May 11, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Enzalutamide: a novel anti-androgen with prolonged survival rate in CRPC patients
Richa Dhingra, Tina Sharma, Sukhminder Singh
1Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Ferozepur Road, Moga-142 001, India. manavmalhotra99@yahoo.in.
Abstract:
Prostate cancer is the most common malignancy among men found to be the second leading cause of male cancer-related mortality due to development of resistance against androgen deprivation therapy (ADT). With the advancement in understanding of prostate cancer, numbers of agents have been emerged to target Androgen-Receptor (AR) signaling for the treatment of castration resistant prostate cancer (CRPC). Food and Drug Administration (FDA) has recently approved enzalutamide (XTANDI) for the treatment of CRPC. Androgen receptor promotes the prostate cancer progression after transformation. Androgen receptor signaling leads to CRPC when cellular nucleus binds to DNA and increases pro cancer gene expression. In phase ΙΙΙ clinical trial, enzalutamide showed that 160 mg once daily oral administration is well tolerated and significantly enhanced overall survival in men with CRPC after chemotherapy, demonstrated by reduction in the serum prostate specific antigen (PSA) level and increased survival rate by 4.8 months.
Insights
Enzalutamide is an effective treatment for men with castration-resistant prostate cancer (CRPC) after chemotherapy. This oral medication significantly improves overall survival and reduces prostate-specific antigen levels.
Area of Science:
- Oncology
- Urology
Background:
- Prostate cancer is a leading cause of male cancer mortality.
- Resistance to androgen deprivation therapy (ADT) leads to castration-resistant prostate cancer (CRPC).
- Androgen Receptor (AR) signaling drives prostate cancer progression.
Purpose of the Study:
- To evaluate the efficacy and safety of enzalutamide for treating CRPC.
- To assess the impact of enzalutamide on overall survival and prostate-specific antigen (PSA) levels.
Main Methods:
- Phase III clinical trial of enzalutamide in men with CRPC post-chemotherapy.
- Oral administration of 160 mg enzalutamide once daily.
- Monitoring of serum PSA levels and overall survival rates.
Main Results:
- Enzalutamide demonstrated good tolerability.
- Significant enhancement in overall survival observed.
- Reduction in serum PSA levels and increased survival by 4.8 months.
Conclusions:
- Enzalutamide is a well-tolerated and effective treatment for CRPC.
- Enzalutamide offers a significant survival benefit for men with CRPC.
- Targeting AR signaling with enzalutamide is a promising strategy for CRPC treatment.
